- Rivero, Vanessa
- Saiz, María Laura
- Torralba, Daniel
- López-Larrea, Carlos
- Suárez-Álvarez, Beatriz
- DeDiego, Marta L.
This article belongs to the Special Issue Coronaviruses Pathogenesis, Immunity, and Antivirals (2nd Edition)., CD9 protein belongs to a family of proteins called tetraspanins, so named for their four-transmembrane-spanning architectures. These proteins are located in domains in the plasmatic membrane, called tetraspanin-enriched microdomains (TEMs). Several proteases and cellular receptors for virus entry cluster into TEMs, suggesting that TEMs are preferred virus entry portals. Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein mediates virus attachment and entry into cells by binding to human angiotensin-converting enzyme 2 (ACE-2). In addition, the secretory, type-I membrane-bound SARS-CoV-2 S protein is synthesized as a precursor (proS) that undergoes posttranslational cleavages by host cell proteases, such as furin and TMPRSS2. Moreover, it has been shown that neuropilin-1 (NRP1), which is known to bind furin-cleaved substrates, potentiates SARS-CoV-2 infectivity. Our results indicate that CD9 facilitates SARS-CoV-2 infection. In addition, we show how knocking out CD9 leads to a decrease in the expression of NRP1, a protein that improves SARS-CoV-2 infection. Furthermore, we show that CD9 colocalizes with ACE-2, NRP1, furin, and TMPRSS2 at the plasma membrane; that the absence of CD9 decreases the expression of these proteins on the plasma membrane CD9-enriched microdomains, and that CD9 interacts with ACE2. In conclusion, our data suggest that CD9 facilitates SARS-CoV-2 infection and that CD9 brings together different host proteins involved in SARS-CoV-2 attachment and entry into host cells, such as ACE2, NRP1, furin, and TMPRSS2. Importantly, the fact that a blocking antibody targeting CD9 can effectively reduce SARS-CoV-2 titers highlights not only the mechanistic role of CD9 in viral entry but also offers translational potential, suggesting that tetraspanin-targeting antibodies could be developed as therapeutic agents against SARS-CoV-2 and possibly other coronaviruses, with meaningful implications for clinical intervention., This work was supported by grant PID-2021-123810OB-I00, funded by MCIN/AEI/10.13039/501100011033/ and by FEDER; and by grant CNS2022-135276, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, to M.L.D. This work was also funded by FINBA-ISPA through the call for Early-Career Researchers, sponsored by JANSSEN (2021-050-INTRAMURAL NOV-SAALM), to M.L.S. and by PCTI-Plan de Ciencia, Tecnología e Innovación 2024–2027 from the Gobierno del Principado de Asturias (“Ayudas para Grupos de Investigación del Principado de Asturias 2024–2027”, FICYT, Grant IDE/2024/000775 Grupo de Inmunología Traslacional), co-funded by FEDER Funding Program from the European Union and by Instituto de Salud Carlos III (ISCIII) through the projects PI22/00738 and PI23/00567 to C.L.-L. and B.S.-Á. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed